Skip to search formSkip to main contentSkip to account menu

elacytarabine

The lipophilic 5'-elaidic acid ester of the deoxycytidine analog cytosine arabinoside (cytarabine; Ara-C) with potential antineoplastic activity. As… 
National Institutes of Health

Related topics

Related topics

1 relation
CP-4055

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the…
Abstract Unlike cytarabine, cellular entry of Elacytarabine, the elaidic acid ester derivative of cytarabine, is independent of… 
2013
2013
Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts.
AIM The objective of the present study was to determine the in vivo antitumor activity of elacytarabine, the 5'-elaidic acid… 
2012
2012
A somatic EZH2 mutation in childhood acute myeloid leukemia
2012
2012
A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline
Abstract 46 Background Elacytarabine, a fatty acid derivative (elaidic acid ester) of cytarabine, has pharmacokinetic and… 
Review
2011
Review
2011
Elacytarabine – lipid vector technology overcoming drug resistance in acute myeloid leukemia
Introduction: Ara-C (cytarabine arabinoside) is a deoxycytidine analog that has an established role in the treatment of… 
2011
2011
A phase II study of elacytarabine plus idarubicin as second course remission-induction therapy in patients with acute myeloid leukemia.
TPS207 Background: Elacytarabine is a fatty acid derivative (elaidic acid ester) of the antimetabolite cytarabine,which is widely… 
2011
2011
A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline, and Evaluation of the Impact of the…
Abstract 1533 Background: Elacytarabine is a fatty acid derivative (elaidic acid ester) of cytarabine. The mechanism of action is… 
Review
2011
Review
2011
A randomized phase III study of elacytarabine versus limited investigator's choice in patients with refractory acute myeloid leukemia (AML).
TPS206 Background: Elacytarabine is a novel chemical entity developed as an antineoplastic agent. It is a fatty acid derivative… 
2010
2010
Induction of Resistance to the Lipophilic Cytarabine Prodrug Elacytarabine (CP-4055) in CEM Leukemic Cells
The deoxynucleoside analogs cytarabine (Ara-C) and gemcitabine (dFdC) are widely used in the treatment of cancer. Due to their… 
2010
2010
The Activity of the Lipophilic Nucleoside Derivatives Elacytarabine and CP-4126 in a Panel of Tumor Cell Lines Resistant to Nucleoside Analogues
The clinical activity of pyrimidine analogues (araC and gemcitabine) is impaired by different mechanisms of resistance and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)